nature portfolio

Corresponding author(s):	Sina Majidian; Justin Zook
Last updated by author(s):	Sen 15 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

- .			
St	ˈat	ıst	ICS

For	all st	tatistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Coi	nfirmed
	x	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	x	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
x		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
x		A description of all covariates tested
X		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	x	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
x		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable</i> .
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
X		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

No software was used for data collection.

Data analysis

The snakemake pipeline for generating stratifications are available at https://github.com/usnistgov/giab-stratifications. A copy of the GitHub repository and HTML output of the snakemake pipeline are archived at Zenodo at https://zenodo.org/records/11176260. Publicly available software for analyzing data includes seqtk v1.3-r106, bedtools v2.27.1, tabix v1.9, minimap2 v2.24, bedtools v2.30.0 and GEMMapper pre-release 3.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All versions of the genome stratifications up to v3.5 (the latest as of this writing) are available on an FTP site hosted by NCBI here at https://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/release/genome-stratifications/.

Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation)</u>, and sexual orientation and race, ethnicity and racism.

<u>nd sexual orientation</u> and <u>race, ethnicity and racism</u> .				
Reporting on sex and gender	The GIAB HG002 sample was used.			
Reporting on race, ethnicity, or other socially relevant groupings	Please specify the socially constructed or socially relevant categorization variable(s) used in your manuscript and explain why they were used. Please note that such variables should not be used as proxies for other socially constructed/relevant variables (for example, race or ethnicity should not be used as a proxy for socioeconomic status). Provide clear definitions of the relevant terms used, how they were provided (by the participants/respondents, the researchers, or third parties), and the method(s) used to classify people into the different categories (e.g. self-report, census or administrative data, social media data, etc.) Please provide details about how you controlled for confounding variables in your analyses.			
Population characteristics	Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."			
Recruitment	Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.			
Ethics oversight	The participant was originally consented as part of the Harvard Personal Genome Project			
lote that full information on the appr	oval of the study protocol must also be provided in the manuscript.			
ield-specific re	porting			
lease select the one below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences B	ehavioural & social sciences			
or a reference copy of the document with	all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

1 human genome was used. The main focus of the study is the human reference genome.

Data exclusions

No data was excluded.

Replication

This work focuses on reference gnome and 1 sample was used to investigate future stratifications.

Randomization

Randomization is not relevant to this study.

Blinding

No information is blinded.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

n/a Involved in the study	
X Antibodies X ChIP-seq	
Eukaryotic cell lines X Flow cytometry	
Palaeontology and archaeology MRI-based neuroimaging	
Animals and other organisms	
Clinical data	
Dual use research of concern	
Plants	

Plants

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to

Authentication

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosiacism, off-target gene editing) were examined.